These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Assessment of quality of life using three activity questionnaires in heart failure patients after monthly, intermittent administration of levosimendan during a six-month period.
    Author: Papadopoulou EF, Mavrogeni SI, Dritsas A, Cokkinos DV.
    Journal: Hellenic J Cardiol; 2009; 50(4):269-74. PubMed ID: 19622496.
    Abstract:
    INTRODUCTION: Quality of life (QOL) in heart failure patients is severely compromised by the symptoms of the disease. Acute administration of levosimendan improves patients' symptoms for intervals of 7-10 days. The aim of this study was to assess the QOL in heart failure patients, after monthly, intermittent administration of levosimendan for a 6-month period, using 3 activity questionnaires: Specific Activity Questionnaire (SAQ), Left Ventricular Dysfunction 36 (LVD 36), and Minnesota Living with Heart Failure Questionnaire (LIhFE). METHODS: We prospectively studied 20 patients, age 61.0 +/- 15.7 years (mean +/- SD) with heart failure (NYHA III and IV). Levosimendan was administered intravenously for 24 hours (dose 0.1 mg/kg/min), 1 day every month for a 6-month period. Patients were asked to answer the questions of the 3 activity questionnaires SAQ, LVD36 and LIhFE before and after the end of the 6-month period. RESULTS: For the LIhFE (the best score is 0 and the worst 105) before levosimendan the score was 35.4 +/- 18.6 and after 6 months 22.2 +/- 13.0 (p<0.0001). SAQ (worst score is 0 and the best is 9) before levosimendan was 4.2 +/- 1.6 and after 6 months 4.7 +/- 1.3 (p<0.05). For the LVD36 (more ;right' answers, more severe condition) before levosimendan values were 52.6 +/- 26.2 and after 6 months 27.4 +/- 17.3 (p<0.0001). Before levosimendan patients had a mean left ventricular ejection fraction (LVEF) 30.3 +/- 6.9, while after 6 months the LVEF was 32.1 +/- 7.4 (p=0.01). CONCLUSIONS: Levosimendan treatment improved both objective echocardiographic measurements and the subjective QOL questionnaires. LIhFE and LVD36 show a significant improvement in QOL in heart failure patients after a 6-month period of monthly intermittent administration of levosimendan. The SAQ showed a very small improvement, because it describes more strenuous activity, a situation unusual for these patients, who are severely symptom limited.
    [Abstract] [Full Text] [Related] [New Search]